Login to Your Account

Financings Roundup

Regulus Therapeutics to Raise $42.8M in a Public Offering

By Catherine Shaffer
Staff Writer

Wednesday, July 17, 2013
A new public offering of 4.5 million shares of common stock at $9.50 per share will help to float Regulus Therapeutics Inc.'s pipeline of drugs targeting microRNAs, including its lead compound RG-101 for hepatitis C virus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription